What is the current state of obesity in India?

Nearly one in four Indian adults is obese, with the condition increasingly prevalent in rural areas and across various socioeconomic groups.

When were GLP-1 RA drugs launched in India?

GLP-1 Receptor Agonist (GLP-1 RA) drugs, such as Ozempic, Wegovy, and Mounjaro, were launched in India during 2025.

What are the health benefits of managing obesity?

Managing obesity can lead to improved metabolic health, better blood sugar control, reduced cardiovascular risk, and reversal of conditions like fatty liver disease.

Home / Health / New Obesity Drugs Launched in India for 2025

New Obesity Drugs Launched in India for 2025

24 Jan

•

Summary

Obesity is a global health crisis, affecting over a billion people worldwide.
GLP-1 RA drugs, like Ozempic, Wegovy, and Mounjaro, launched in India in 2025.
Nearly one in four Indians are now obese, with rural and lower-income groups affected.

New Obesity Drugs Launched in India for 2025

Obesity has become a critical global public health issue, with over a billion people affected worldwide and rising prevalence in nearly every nation, including India. Recent data indicates that almost one in four Indian adults is now obese, a trend observed in both urban and rural areas, and across socioeconomic strata.

The year 2025 marked a significant development with the introduction of GLP-1 Receptor Agonist (GLP-1 RA) drugs in India. These medications, including Ozempic, Wegovy, and Mounjaro, mimic the body's GLP-1 hormone to help manage Type 2 diabetes and chronic obesity. They work by regulating blood sugar, slowing digestion, and reducing appetite, contributing to sustained weight loss.

A survey revealed that while 6 in 10 Indians are already dealing with obesity-related complications, a substantial portion still views obesity as a lifestyle choice rather than a medical condition. Awareness of prescription treatments like GLP-1 RAs remains low, with only 16% of respondents well-informed.